TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02022540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Study: NCT00995852

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBV Implantation
Description: In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBV Implantation
Description: In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration
Study: NCT03166930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spasticity Take Control
Description: Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching for People with MS: An Illustrated Manual
Description: Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
Study: NCT04391920

Intervention type: DEVICE
Intervention: CytoSorb 300 mL device
Description: CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
Study: NCT01138410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCIB1
Description: Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
Study: NCT01657305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10, non-adhesive wound dressing
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-adhesive wound dressing only
Description: Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Study: NCT02522468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Localization
Study: NCT01673516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The SymplicityTM Renal Denervation System
Description: For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The HOTMAN® System
Description: Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co
Study: NCT02259114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Birabresib 10, 20 and/or 40 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Birabresib 10, 20 and/or 40 mg oral capsules
Study: NCT03981328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitoring System
Description: Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-monitored blood glucose
Description: Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
Study: NCT00658268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: 60 mg/ml, 10 ml, single dose mixed in bone graft at operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml, single dose mixed in bone graft at operation
Study: NCT04734132

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa
Description: Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
Study: NCT03920891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Pulmonary Vein isolation
Description: 1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation
Description: 1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study: NCT00699101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conture Multi-Lumen Balloon
Description: Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
Study: NCT01564342

Intervention type: PROCEDURE
Group type: OTHER
Intervention: wound irrigation with study fluid
Description: wounds were either irrigated with sterile normal saline or tap water.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: wound irrigation with study fluid
Description: wounds were either irrigated with sterile normal saline or tap water.
Study: NCT00938301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04455242
Description: Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PIC matching in appearance to PF-04455242 will be used to administer placebo.
Study: NCT02842593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-repetition, heavier-load
Description: 8-12 reps/set at \~80% 1 repetition maximum
Study: NCT01098838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Study: NCT03751592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
Study: NCT04473144

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ulinastatin
Description: In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
Study: NCT02553161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral Psychotherapy
Description: All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
Study: NCT02842593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher-repetition, lighter-load
Description: 20-25 reps/set at \~30% 1 repetition maximum
Study: NCT06098326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, fludarabine, and antithymocyte globulin
Description: 1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)
Study: NCT02382588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gancyclovir gel
Description: 0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypromellose gel
Description: 0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
Study: NCT06033625

Intervention type: PROCEDURE
Intervention: CEMENTLESS TOTAL KNEE REPLACEMENT
Description: CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
Study: NCT00168519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprusside, pentalong, imdur, AICAR, isoptin
Description: Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)
Study: NCT04033107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will orally take metformin 4g daily.
Study: NCT01405807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
Study: NCT03352596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low frutose diet
Study: NCT00779870

Intervention type: OTHER
Intervention: bronchoscopy
Description: bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies

Intervention type: OTHER
Intervention: bronchoscopy
Description: bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies

Intervention type: OTHER
Intervention: bronchoscopy
Description: bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies

Intervention type: OTHER
Intervention: bronchoscopy
Description: bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
Study: NCT00134069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT02759913

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
Study: NCT00546481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Description: 0.6 micrograms/kg every 2 weeks
Study: NCT02086097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol
Description: 25m of dexketoprofen (oral intake) every 8 hours
Study: NCT01476384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
Study: NCT02086097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 600 mg of Ibuprofen (Oral Intake) every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: INACTIVE SUGAR PILLS
Study: NCT00525486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine extended release
Description: Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
Study: NCT01149369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
Study: NCT01134237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urokinase
Description: intrapleural urokinase injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline as a placebo for control arm
Study: NCT04071756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Tazarotene
Description: This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect, used as a control in testing new drugs
Study: NCT02568644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extract of ginger
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous ketoprofen
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
Study: NCT02275377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham IMT
Description: Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
Study: NCT02298452

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aid.
Description: The hearing aid will be fitted to the individual hearing loss of the subject.
Study: NCT03298724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachers and Parents as Partners
Description: A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
Study: NCT00203216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study: NCT02459782

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
Description: Landmark Guided single injection vs Ultrasound guided dual quadrant injection
Study: NCT04447482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB with image-guided lung biopsy
Description: Electromagnetic navigational bronchoscopy system with tip tracked instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bronchoscopy guided by Fluoroscopy
Description: Bronchoscopic lung biopsy with fluoroscopy.
Study: NCT05661994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Description: Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group.
Study: NCT01476384

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 ml water
Study: NCT00987012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Twice daily ingestion of pomegranate juice over 4-5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Twice daily ingestion of placebo drink over 4-5 days
Study: NCT00757926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]
Description: Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.